Login to Your Account



FDA lifts clinical hold on Neuroderm trials for drug-device combo in PD

By Michael Fitzhugh
Staff Writer

Friday, May 8, 2015
Neuroderm Ltd. shares (NASDAQ:NDRM) rose $1.24, or 10.9 percent, to close at $12.62 on Friday as investors welcomed the lifting of an FDA clinical hold that was blocking progress on U.S. studies of the company's Parkinson's disease treatments ND0612H and ND0612L.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription